Biography

1. Research Interest

Clinical and fundamental research in the field of organ transplantation.

2. Educational Background

1984.08 Bachelor of Medical Science, Clinical College of China Medical University.

1998.08 Doctor of Medicine, Surgery, School of Medicine, Nihon University.

3.Work Experience

1984.08-1998.08 Surgeon, Surgical Department, Tianjin First Central Hospital.

1998.08-2005.03 Director of Organ Transplant Department and Organ Transplant Research Institute, Tianjin First Central Hospital.

2005.03-2007.10 Vice-President of Tianjin First Central Hospital. Director of Organ Transplant Research Institute, Tianjin First Central Hospital.

2007.10-2010.12 President of Tianjin First Central Hospital. Director of Organ Transplant Research Institute, Tianjin First Central Hospital.

2010.12-President of Tianjin First Central Hospital. Director of Organ Transplant Research Institute, Tianjin First Central Hospital. President of Tianjin Occupational Diseases Precaution and Therapeutic Hospital (Tianjin Workers’ Hospital).

4. Awards

1). Second Prize of National Science and Technology Progress Award“Clinical research and application of liver transplantation.”

2). First Prize of Tianjin Science and Technology Progress Award. “Changes of biological characteristics of hepatitis B virus after liver transplantation and its application.”

3). First Prize of Sichuan Science and Technology Award. “Preparation and clinical application of intravenous hepatitis B human immunoglobulin.”

4). First Prize of the Chinese Armed Police Force. “Comprehensive prevention and treatment of recurrent hepatitis B after liver transplantation.”

5). First Prize of the Chinese Armed Police Force. “Prevention and treatment of recurrent primary liver cancer after liver transplantation.”

6). Second Prize of Chinese Medical Science and Technology Award. “Clinical study and application of liver transplantation in the treatment of hepatitis B virus associated liver disease.”

7). Second Prize of Tianjin Science and Technology Progress Award. “Liver transplantation in the treatment of terminal stage hepatitis B cirrhosis. ”

8). Third Prize of the Science and Technology Awards of Chinese Anti-Cancer Association. “The study of the mechanism and countermeasure of liver tumor recurrence after liver transplantation .”

5. Social Service

1). Director of China Organ Donation Administrative Center.

2). Chief Expert of Organ Transplantation in Core Group of the Central Committee of Health.

3). Director of the Seventh Board of Tianjin Medical Association.

4). Vice-Chairman of Chinese Research Hospital Association.

5). Chief Scientific Adviser of Tianjin International Joint Academy of Biomedicine.

6). Deputy Chairman of the First Academic Committee of Tianjin Institute of Integrated Chinese and Western Medicine.

7). Visiting Professor of the Department of Medicine, Teikyo University, Japan.

8).Chief Editor of the Journal of Chinese Critical Care Medicine.

9).Deputy Chief Editor of Chinese Journal of Organ Transplantation.

Achievements

1. National Top Ten Science and Technology Workers.

2. Ho Leung Ho Lee technological Progress Award.

3. Wu Jieping Medical Research Award-Paul Yang Sen Pharmaceutical Research Award.

4.Top Ten Most Influential Science and Technology Innovations in 2013.

5. Chinese Physician Prize.

6. National Achievement Award of Returned Overseas Chinese Talents.

7. Outstanding Contribution of Young and Middle-aged Experts of National Health Commission of the People’s Republic of China.

Peer-Reviewed Journal Papers

1.Yang Y, Song HL, Zhang W, Wu BJ, Fu NN, Zheng WP, Don C, Shen ZY*. Reduction of acute rejection by bone marrow mesenchymal stem cells during rat Small bowel transplantation. PLOS One, 2014，9(12): e114528 (corresponding author) （IF：3.234）

2.Shi Y, Zhang W, Deng YL, Zhang YM , Zhang QS, Zhang WY, Zheng H, Pan C, Shen ZY*. Magnetic ring anastomosis of suprahepatic vena cava: novel technique for liver transplantation in rat. Transpl Int, 2015, 28(1): 89-94 (corresponding author) （IF：2.599）

3.Yang Y, Song HL, Zhang W, Wu BJ, Fu NN, Zheng WP, Don C, Shen ZY*. Reduction of acute rejection by bone marrow mesenchymal stem cells during rat Small bowel transplantation. PLOS One, 2014，9(12): e114528 (corresponding author) （IF：3.234）

4.Wang K, Jiang WT, Deng YL, Pan C, Shen ZY*. Effect of donor age on graft function and long-term survival of recipients undergoing living donor liver transplantation. Hepatobiliary Pancreat Dis Int, 2015,14(1):50-55. (corresponding author) （IF：1.517）

5.Wu B, Wang K, Mo CB, Shen ZY*.De novo malignancies in renal transplant recipients experience at a single center in China. Int J Exp Med, 2015,8(2):2911-2916 (corresponding author) （IF：1.277）

6.Wu D, Shen ZY*, Zhang YM*, Wang J, Zheng H, Deng YL, Pan C. Effect of liver transplantation in combined hepatocellular and cholangiocellular carcinoma: a case series. BMC Cancer,2015,15(1):232 (co-corresponding author) （IF：3.362）

7.Li J, Cai JZ, Guo QJ, Li JJ, Sun XY, Hu ZD, David KC Cooper, Shen ZY*. Liver transplantation for a giant mesenchymal hamartoma of the liver in an adult: Case report and review of the literature. World J Gastroenterol, 2015,21(20):6409-6416 (corresponding author) （IF：2.433）

8.Liu T, Song HL, Zheng WP, Shen ZY*. Inhibition of HBV Replication in HepG2.2.15 Cells by Human Peripheral Blood Mononuclear Cell-Derived Dendritic Cells. Ann Clin Lab Sci, 2015,45(5):495-501(corresponding author) （IF：0.91）

9.Liu T, Zu CH, Wang SS, Song HL, Wang ZL, Xu XN, Liu HS, Wang YL, Shen ZY*. PIK3C2A mRNA functions as a miR-124 sponge to facilitate CD151 expression and enhance malignancy of hepatocellular carcinoma cells. Oncotarget, 2016,30:1-14. (corresponding author) （IF：5.168）

10.Li SP, Xu HX, Yu T, He JD, Wang Z, Xu YJ, Wang CY, Zhang HM, Zhang RX, Yao Z, Shen ZY*. LncRNA HULC enhances epithelial-mesenchymal transition to promote tumorigenesis and metastasis of hepatocellular carcinoma via the miR-200a-3p/ZEB1 signaling pathway. Oncotarget, 2016,7(27):42431-42446. (corresponding author) (IF:5.168)

11.Wang LJ, Liu ZR, Zhang Ym, Zheng H, Pan C, Deng Yl, Shen ZY*. Clinical analysis of liver transplantation for benign liver tumor. Int J Clin Med, 2016,9(11):22691-22695. (corresponding author) （IF：1.069）

12.Shen ZY, Wu B, Liu T, Yang Y, Yin ML, Zheng WP, Zhang BY, Song HL. Immunomodulatory effects of bone marrow mesenchymal stem cells overexpressing heme oxygenase-1: Protective effects on acute rejection following reduced-size liver transplantation in a rat model. Cell Immunol. 2017 Mar;313:10-24.

13.Zhang ZB, Gao W, Liu L, Shi Y, Ma N, Shen ZY*. Development and Assessment of Normothermic Machine Perfusion Preservation for Extracorporeal Splitting of Pig Liver. Ann Transplant. 2017, 22(22): 507-517. (corresponding author)

14.Yin ML, Song HL, Yang Y, Zheng WP, Liu T, Shen ZY*. Effect of CXCR3/HO-1 genes modified bone marrow mesenchymal stem cells on small bowel transplant rejection. World J Gastroenterol. 2017;23(22): 4016-4038. (corresponding author)

15.Meng XC, Shen ZY*Alterations of Serum IP-10 and TARC in Patients with Early Acute Rejection after Liver Transplantation. Cell Physiol Biochem.2017.（IF：5.104）

16.Zou JQ,Liu TL, Wang SS,Shen ZY* Ethylenecarbodiimide-fixed splenocytes carrying whole islet antigens decrease the incidence of diabetes in NOD mice via down-regulation of effector memory T cells and autoantibodies. Endocrine Journal. 2018（IF：1.911）

17. Li JJ, Cai JZ, Shen ZY* effect of graft size matching on pediatric living-donor liver transplantation at s single center.Clinical Transplantation.20158（IF：1.865）

18. Gao W,Shen ZY*intra-operative cholangiography for donor gallbladder-sparing left lateral hepatic lobectomy in pediatric living donor liver transplantation. Int J Clin Exp Med.2018. （IF：1.069）

Projects

1. Project of Tianjin Municipal Science and Technology Commission: Tianjin Organ Transplant Clinical Medicine Research Center. 2018.04-2019.03. Project Leader.

2. International S&T Cooperation Program of China-Canada: Novel Device for organ preservation and evaluation. Project Number: 2015DFG31850. 2015.04-2018.03. Project Leader.

3. Tianjin Science and Technology Project: Treatment of Small-for-size Syndrome with temporary intermediate auxiliary allograft partial liver transplantation. Project Number: 14RCGFSY00147, 2014.10-2018.03. Project Leader.

4. National High-tech R&D Program (863 Program): Key techniques of Organ Transplantation. Project Number: 2012AA021000. 2012.1-2015.12, Chief Expert.

5.National Natural Science Foundation of China (General Program): The Study of HBV specific immunologic effector cell preventing the recurrence of Hepatitis B after liver Transplantation. Project Number: 81170444. 2012.01-2014.12. Project Leader.